Page 271 - 2021_03-Haematologica-web

Letters to the Editor
human erythropoietic protoporphyria. Am J Hum Genet. 2019;
104(2):341-347.
8. Piomelli S, Poh-Fitzpatrick MB, Seaman C, Skolnick LM, Berdon
WE. Complete suppression of the symptoms of congenital erythro- poietic porphyria by long-term treatment with high-level transfu- sions. N Engl J Med. 1986;314(16):1029-1031.
9. Peinado CM, Díaz De Heredia C, To-Figueras J, et al. Successful treatment of congenital erythropoietic porphyria using matched unrelated hematopoietic stem cell transplantation. Pediatr Dermatol. 2013;30(4):484-489.
10. Kontoghiorghes GJ, Kontoghiorghe CN. Efficacy and safety of iron- chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with non-transfusion- dependent thalassemia syndromes. Drug Des Devel Ther. 2016; 10:465-481.
11. Naessens V, Ward R, Kuo KHM. A proposed treatment algorithm
for adults with haemoglobin SC disease. Br J Haematol.
2018;182(4):607-609.
12. Lionnet F, Hammoudi N, Stojanovic KS, et al. Hemoglobin sickle cell
disease complications: a clinical study of 179 cases. Haematologica.
2012;97(8):1136-1141.
13. Katugampola RP, Badminton MN, Finlay AY, et al. Congenital ery-
thropoietic porphyria: a single-observer clinical study of 29 cases. Br
J Dermatol. 2012;167(4):901-913.
14. Barman-Aksözen J, Minder EI, Schubiger C, Biolcati G, Schneider-
Yin X. In ferrochelatase-deficient protoporphyria patients, ALAS2 expression is enhanced and erythrocytic protoporphyrin concentra- tion correlates with iron availability. Blood Cells Mol Dis. 2015;54(1):71-77.
15. Deacon AC, Elder GH. Front line tests for the investigation of sus- pected porphyria. J Clin Pathol. 2001;54(7):500-507.
haematologica | 2021; 106(3)
917